BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Business

  Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

  Teva Pharmaceutical Industries Ltd. reported results for the quarter ended March 31, 2024.

  May 8, 2024

   · 

  52 min read
• Drug Development

  Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

  Alterity Therapeutics announced that an independent Data Monitoring Committee has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned.

  May 8, 2024

   · 

  6 min read
• Business

  Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024

  Verrica Pharmaceuticals Inc. announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2024.

  May 8, 2024

   · 

  1 min read
• Drug Development

  Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

  Cytokinetics, Incorporated announced topline data from the Phase 1 study of CK-4021586.

  May 8, 2024

   · 

  7 min read
• Drug Development

  BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity

  BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced its development of a novel exosome-based biologic program targeting obesity.

  May 8, 2024

   · 

  5 min read
• BioMidwest

  NeuroTherapia Receives Grant from Alzheimer’s Association for Development of First-in-Class Drug for Alzheimer’s Disease

  NeuroTherapia, an early-stage clinical pharmaceutical company, announced that it has received a grant from the Alzheimer’s Association Part the Cloud program for the development of its first-in-class drug, NTRX-07, for the treatment of Alzheimer’s disease.

  May 8, 2024

   · 

  2 min read
• Drug Development

  Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

  Carisma Therapeutics Inc. announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treatment of liver fibrosis.

  May 8, 2024

   · 

  6 min read
• Pharm Country

  Intra-Cellular Therapies to Participate in Two Upcoming May 2024 Investor Conferences

  Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will participate in two upcoming investor conferences.

  May 8, 2024

   · 

  1 min read
• Business

  Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, reported business highlights and financial results for the first quarter ended March 31, 2024.

  May 8, 2024

   · 

  14 min read
• Business

  Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

  Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported its financial results for the quarter ended March 31, 2024, and provided a business update.

  May 8, 2024

   · 

  13 min read